Lung India (Jun 2024)

Profile of patients referred for lung transplant and their transplant-free survival

  • Vidushi Rathi,
  • Pawan Tiwari,
  • Sandeep Seth,
  • Vijay Hadda,
  • Karan Madan,
  • Shubham Agarwal,
  • Arti Vij,
  • Milind Hote,
  • Manoj Sahu,
  • Saurabh Mittal,
  • Randeep Guleria,
  • Shivam Pandey,
  • Ravindra M. Pandey,
  • Anant Mohan

DOI
https://doi.org/10.4103/lungindia.lungindia_515_23
Journal volume & issue
Vol. 41, no. 4
pp. 265 – 271

Abstract

Read online

Introduction Lung transplant (LTx) is a potential treatment option for all patients with chronic, end-stage respiratory disease, who are refractory to optimal medical therapy or where no medical therapy exists. In India, LTx is still in its evolving stages and published literature is sparse. The current study was carried out to study the selection criteria for lung transplant and to evaluate the clinical and socio-economic profile of patients referred for the same at a tertiary health care facility. Methods The study was a descriptive, prospective, observational study. All adults referred for lung transplant were evaluated for clinical and laboratory profiles. All enrolled patients were assessed for presence of referral criteria, listing criteria, contraindications, and willingness for lung transplant. These patients were followed up for 2 years for transplant-free survival, and the Cox proportional hazards model was used to determine independent predictors of all-cause mortality. Results A total of 103 were included in study. The most common diagnosis was interstitial lung disease (57.2%), followed by bronchiectasis (17.5%) and COPD (13.6%). Most patients were referred for LTx at an advanced stage as 90% met listing criteria. Fifty-four (52.4%) patients had an absolute or relative contraindication to transplant; however, the majority of those contraindications were modifiable. Patients with a lower socio-economic status were less likely to be willing for LTx. The median survival was 757 days. A 6-minute walk distance (6MWD) lesser than 250 m was found to be an independent predictor of mortality. Conclusion Making patients aware about lung transplant early in their treatment may give them sufficient time to come to terms with their disease and understand the risk and benefits associated. Efforts should be focused on screening and early treatment of reversible contraindications for the eligible patients. Patients with 6MWD < 250 m are at increased risk of mortality.

Keywords